ATI Pathophysiology Final Exam Related

Review ATI Pathophysiology Final Exam related questions and content

A nurse is teaching a patient about the use of raloxifene (Evista) for the prevention of osteoporosis. What is the primary therapeutic action of this medication?

  • A. It decreases the absorption of calcium from the intestines.
  • B. It decreases bone resorption and increases bone density.
  • C. It increases the excretion of calcium through the kidneys.
  • D. It stimulates the formation of new bone.
Correct Answer: B

Rationale: The correct answer is B. Raloxifene, a selective estrogen receptor modulator (SERM), works by decreasing bone resorption and increasing bone density. This action helps in preventing osteoporosis by maintaining bone strength. Choice A is incorrect as raloxifene does not affect the absorption of calcium from the intestines. Choice C is incorrect as raloxifene does not increase the excretion of calcium through the kidneys. Choice D is incorrect as raloxifene does not directly stimulate the formation of new bone; instead, it primarily works by reducing bone loss.